Alterations of maternal serum and placental follistatin-like 3 and myostatin in pre-eclampsiajog

Journal of Obstetrics and Gynaecology Research

Volumn 38, Issue 7, 2012, Pages 988-996

  Guo, Jing ^a   Tian, Ting ^a   Lu, Donghong ^a   Xia, Guiyu ^b   Wang, Hanzhi ^a   Dong, Minyue ^a,b,c  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Zhejiang Province   (China)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Follistatin like 3; Myostatin; Placenta; Pre eclampsia; Serum

Indexed keywords

BINDING PROTEIN; MYOSTATIN; PROTEIN FSTL3; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; PLACENTA; PREECLAMPSIA; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADULT; CROSS-SECTIONAL STUDIES; FEMALE; FOLLISTATIN-RELATED PROTEINS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMANS; MYOSTATIN; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX;

EID: 84864599052     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2011.01823.x     Document Type: Article

References (41)

1. Roberts JM, Gammill HS. Pre-eclampsia: Recent insights. Hypertension 2005; 46: 1243-1249.
2. Redman CW, Sargent IL. Latest advances in understanding pre-eclampsia. Science 2005; 308: 1592-1594.
3. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005; 365: 785-799.
4. Bell MJ. A historical overview of pre-eclampsia-eclampsia. J Obstet Gynecol Neonatal Nurs 2010; 39: 510-518.
5. Mutter WP, Karumanchi SA. Molecular mechanisms of pre-eclampsia. Microvasc Res 2008; 75: 1-8.
6. Silver HM, Lambert-Messerlian GM, Reis FM, Diblasio AM, Petraglia F, Canick JA. Mechanism of increased maternal serum total activin a and inhibin a in pre-eclampsia. J Soc Gynecol Investig 2002; 9: 308-312.
7. Casagrandi D, Bearfield C, Geary J, Redman CW, Muttukrishna S. Inhibin, activin, follistatin, activin receptors and beta-glycan gene expression in the placental tissue of patients with pre-eclampsia. Mol Hum Reprod 2003; 9: 199-203.
8. Khalil A, Jauniaux E, Harrington K, Muttukrishna S. Placental production and maternal serum and urine levels of inhibin A and activin A are modified by antihypertensive therapy in hypertensive disorders of pregnancy. Clin Endocrinol (Oxf) 2009; 70: 924-931.
9. Muttukrishna S, Knight PG, Groome NP, Redman CW, Ledger WL. Activin A and inhibin A as possible endocrine markers for pre-eclampsia. Lancet 1997; 349: 1285-1288.
10. Yu J, Shixia CZ,Wu Y, Duan T. The study of inhibin A, activin A, placental growth factor and uterine artery Doppler pulsatility index to predict pre-eclampsia. Ultrasound Obstet Gynecol 2011; 37: 528-533.
11. Reddy A, Suri S, Sargent IL, Redman CW, Muttukrishna S. Maternal circulating levels of activin A, inhibin A, sFlt-1 and endoglin at parturition in normal pregnancy and preeclampsia. PLoS ONE 2009; 4: E4553.
12. Jones RL, Stoikos C, Findlay JK, Salamonsen LA. TGF-beta superfamily expression and actions in the endometrium and placenta. Reproduction 2006; 132: 217-232.
13. Kitisin K, Saha T, Blake T et al. Tgf-Beta signaling in development. Sci STKE 2007; 2007: Cm1.
14. Zhao L, Shang T, Wang YL, Tang S, Li H, Liu ZH. Study on the relationship between activin A, follistatin and preeclampsia. Zhonghua Fu Chan Ke Za Zhi 2003; 38: 676-679.
15. Keelan JA, Taylor R, Schellenberg JC, Groome NP, Mitchell MD, North RA. Serum activin A, inhibin A, and follistatin concentrations in pre-eclampsia or small for gestational age pregnancies. Obstet Gynecol 2002; 99: 267-274.
16. Tsuchida K. Activins, myostatin and related TGF-beta family members as novel therapeutic targets for endocrine, metabolic and immune disorders. Curr Drug Targets Immune Endocr Metabol Disord 2004; 4: 157-166.
17. Tsuchida K, Arai KY, Kuramoto Y, Yamakawa N, Hasegawa Y, Sugino H. Identification and characterization of a novel follistatin-like protein as a binding protein for the TGF-beta family. J Biol Chem 2000; 275: 40788-40796.
18. Pryor-Koishi K, Nishizawa H, Kato T et al. Overproduction of the follistatin-related gene protein in the placenta and maternal serum of women with pre-eclampsia. BJOG 2007; 114: 1128-1137.
19. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 2002; 99: 159-167.
20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001; 25: 402-408.
21. Schmittgen TD, Livak KJ. Analysis real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3: 1101-1108.
22. Petraglia F, Aguzzoli L, Gallinelli A et al. Hypertension in pregnancy: Changes in activin A maternal serum concentration. Placenta 1995; 16: 447-454.
23. Hamar BD, Buhimschi IA, Sfakianaki AK et al. Serum and urine inhibin A but not free activin A are endocrine biomarkers of severe pre-eclampsia. Am J Obstet Gynecol 2006; 195: 1636-1645.
24. Diesch CH, Holzgreve W, Hahn S, Zhong XY. Comparison of activin A and cell-free fetal DNA levels in the maternal plasma from patients at high risk of pre-eclampsia. Prenat Diagn 2006; 26: 1267-1270.
25. Nishizawa H, Pryor-Koishi K, Kato T, Kowa H, Kurahashi H, Udagawa Y. Microarray analysis of differentially expressed fetal genes in placental tissue derived from early and late onset severe pre-eclampsia. Placenta 2007; 28: 487-497.
26. Florio P, Ciarmela P, Luisi S et al. Pre-eclampsia with fetal growth restriction: Placental and serum activin A and inhibin A levels. Gynecol Endocrinol 2002; 16: 265-272.
27. Hoegh AM, Borup R, Nielsen FC, Sorensen S, Hviid TV. Gene expression profiling of placentas affected by pre-eclampsia. J Biomed Biotechnol 2010; 2010: 785-545.
28. D'Antona D, Reis FM, Benedetto C et al. Increased maternal serum activin A but not follistatin levels in pregnant women with hypertensive disorders. J Endocrinol 2000; 1651: 157-162.
29. Phupong V, Paiwattananupant K, Honsawek S. Inhibin A levels and severity of pre-eclampsia. Arch Gynecol Obstet 2009; 280: 183-186.
30. Spencer K, Cowans NJ, Nicolaides KH. Maternal serum inhibin-A and activin-A levels in the first trimester of pregnancies developing pre-eclampsia. Ultrasound Obstet Gynecol 2008; 32: 622-626.
31. Birdsall M, Ledger W, Groome N, Abdalla H, Muttukrishna S. Inhibin A and activin A in the first trimester of human pregnancy. J Clin Endocrinol Metab 1997; 82: 1557-1560.
32. Muttukrishna S, George L, Fowler PA, Groome NP, Knight PG. Measurement of serum concentrations of inhibin-A (alpha-beta A dimer) during human pregnancy. Clin Endocrinol (Oxf) 1995; 42: 391-397.
33. Muttukrishna S, North RA, Morri S et al. Serum inhibinA and activin A are elevated prior to the onset of pre-eclampsia. Hum Reprod 2000; 15: 1640-1645.
34. Plevyak MP, Lambert-Messerlian GM, Farina A, Groome NP, Canick JA, Silver HM. Concentration of serum total activin A and inhibin A in preterm and term labor patients: A crosssectional study. J Soc Gynecol Investig 2003; 10: 231-236.
35. Muttukrishna S, Fowler PA, George L, Groome NP, Knight PG. Changes in peripheral serum levels of total activin A during the human menstrual cycle and pregnancy. J Clin Endocrinol Metab 1996; 81: 3328-3334.
36. Schneider-Kolsky M, D'Antona D, Evans LW et al. Maternal serum total activinA and follistatin in pregnancy and parturition. BJOG 2000; 107: 995-1000.
37. Biron-Shental T, Schaiff WT, Rimon E, Shim TL, Nelson DM, Sadovsky Y. Hypoxia enhances the expression of follistatinlike 3 in term human trophoblasts. Placenta 2008; 29: 51-57.
38. Zhao B, Wall RJ, Yang J. Transgenic expression of myostatin propeptide prevents diet-induced obesity and insulin resistance. Biochem Biophys Res Commun 2005; 337: 248-255.
39. Feldman BJ, Streeper RS, Fatese RV Jr, Yamamoto KR. Myostatin modulates adipogenesis to generate adipocytes with favorable metabolic effects. Proc Natl Acad Sci U S A 2006; 103: 15675-15680.
40. Guo T, Jou W, Chanturiya T, Portas J, Gavrilova O, McPherron AC. Myostatin inhibition in muscle, but not adipose tissue, decreases fat mass and improve insulin sensitivity. PLoS ONE 2009; 4: E4937.
41. Wilkes JJ, Lloyd DJ, Gekakis N. Loss-of-function mutation in myostatin reduces tumor necrosis factor alpha production and protects liver against obesity-induced insulin resistance. Diabetes 2009; 58: 1133-1143.